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Abstract: Efficient catabolic metabolism of adenosine triphosphate (ATP) and reduced nicotinamide
adenine dinucleotide phosphate (NADPH) is essentially required for cancer cell survival, especially
in metastatic cancer progression. Epithelial–mesenchymal transition (EMT) plays an important
role in metabolic rewiring of cancer cells as well as in phenotypic conversion and therapeutic
resistance. Snail (SNAI1), a well-known inducer of cancer EMT, is critical in providing ATP and
NADPH via suppression of several gatekeeper genes involving catabolic metabolism, such as
phosphofructokinase 1 (PFK1), fructose-1,6-bisphosphatase 1 (FBP1), and acetyl-CoA carboxylase 2
(ACC2). Paradoxically, PFK1 and FBP1 are counter-opposing and rate-limiting reaction enzymes of
glycolysis and gluconeogenesis, respectively. In this study, we report a distinct metabolic circuit of
catabolic metabolism in breast cancer subtypes. Interestingly, PFKP and FBP1 are inversely correlated
in clinical samples, indicating different metabolic subsets of breast cancer. The luminal types of breast
cancer consist of the pentose phosphate pathway (PPP) subset by suppression of PFKP while the
basal-like subtype (also known as triple negative breast cancer, TNBC) mainly utilizes glycolysis and
mitochondrial fatty acid oxidation (FAO) by loss of FBP1 and ACC2. Notably, PPP remains active
via upregulation of TIGAR in the FBP1-loss basal-like subset, indicating the importance of PPP in
catabolic cancer metabolism. These results indicate different catabolic metabolic circuits and thus
therapeutic strategies in breast cancer subsets.
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1. Introduction
Malignant cancer cells continuously encounter altered environmental conditions of nutrient
deficiency, hypoxia, and acidosis that challenge its survival. Trade-offs between proliferation and
survival are essential for cancer cells to adapt and settle in their dynamic environment [1]. Cancer
cells pursue this balance via metabolic reprogramming of biosynthesis, bioenergetics, and redox
homeostasis [1–3]. The proliferative and survival phenotypes, also termed fast and slow life history,
respectively, require different balances of these metabolic products. Proliferation requires extensive
amounts of biosynthesis, thus avoiding complete consumption of carbons during bioenergy acquisition,
whereas survival is promoted through adequate bioenergy supply enriched by the mitochondria.
Redox power is essential for both fatty acid synthesis (FAS) and oxidative stress, and its homeostasis is
gained by allosteric regulation of its metabolite based on situational requirements [4–6].
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Epithelial–mesenchymal transition (EMT) is a cellular process presented in embryogenesis, wound
healing, and cancer whereby mesenchymal traits of loss of adherence and polarity from epithelial
cells. In addition to phenotypic transition, EMT is involved in stemness, invasiveness, migration
ability, apoptotic resistance, and metabolic reprogramming in cancers [7–11]. The mesenchymal
phenotype has advantages for dissemination, yet structural plasticity is not the only conversion
required for entrance and migration within circulation. Metastasis is highly inefficient, primarily
because cancer cells lose glucose transport caused due to cellular detachment to adjacent epithelial
cells or extracellular matrix [12–15]. To overcome metastatic inefficiency, cancer cells must conduct
oncogenic metabolic reprogramming to compensate for adenosine triphosphate (APT) generation and
reduce its consequence, oxidative stress.
The ATP and reduced nicotinamide adenine dinucleotide phosphate (NADPH) are essential
catabolic metabolites under starved environment, and are controlled by interconnected glycolysis,
gluconeogenesis, pentose phosphate pathway (PPP), and mitochondrial activity such as fatty acid
oxidation (FAO) and tricarboxylic acid (TCA) cycles (Figure 1). Recently, several metabolic enzymes
have been identified as target genes of Snail transcriptional repressor including phosphofructokinase,
platelet (PFKP), fructose-1,6-bisphosphatase 1 (FBP1), and acetyl-CoA carboxylase (ACC2) [16–18].
Snail repressor directly binds to the E-boxes located in proximal promoter of those target genes and
Snail abundance is inversely correlated [16–18]. Interestingly, these Snail target genes are critical
enzymes involving NADPH and ATP generation under glucose-starved environment, supporting the
important role of Snail in catabolic metabolism during metastatic cancer progression. In this article, we
investigate the coordination of metabolic pathways expressed in breast cancer molecular subtypes
underlying EMT-regulated catabolic metabolism.
Figure 1. Metabolic pathways and Snail target enzymes of catabolic metabolism.
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Representative metabolic intermediates and enzymes of PPP, FAO, and the glycolytic pathway that
constitute cancer cell catabolic metabolism in glucose-derived conditions are illustrated. Key metabolic
enzymes (PFK-1, FBP1, and ACC2) targeted by EMT transcription factor Snail during catabolism are
highlighted. Metabolic interaction between PPP, FAO, and the glycolytic pathway via key enzyme
regulation induces the overall carbon flux toward catabolism and promotes cell survival via ATP
and NADPH production. Abbreviations: PPP, pentose phosphate pathway; Glc, glucose; G6P,
glucose 6-phosphate; 6PG, 6-phosphogluconate; Ribu5P, ribulose-5-phosphate; NADPH, reduced
nicotinamide adenine dinucleotide phosphate; Ribo5P, ribose-5-phosphate; Xylulose5P, Xylulose
5-phosphate; GADP, glyceraldehyde 3-phosphate; TKT, transketolase; TALDO1, transaldolase 1;
Sedo7P, sedoheptulose-7P; Ery4P, erythrose 4-phosphate; F6P, fructose 6-phosphate; F2,6-BP, fructose
2,6-bisphosphate; TIGAR, TP53-induced glycolysis and apoptosis regulator; PFK, phosphofructokinase;
FBP, fructose 1,6-bisphosphatase; F1,6BP, fructose 1,6-bisphosphate; DHAP, dihydroxyacetone
phosphate; PEP, phosphoenolpyruvate; PKM2, pyruvate kinase M2; AMK, AMP-activated protein
kinase, ACC2, acetyl-CoA carboxylase 2; CPT1, carnitine palmitoyltransferase I; FAO, fatty acid
oxidation; TCA, tricarboxylic acid.
2. Methods
Publicly available mRNASeq data of human breast cancer samples (BRCA) was downloaded
(https://gdac.broadinstitute.org). The illuminahiseq_rnaseqv2-RSEM_genes_normalized (MD5) was
log2 transformed and the relative transcript abundance of PFKP, ACC2 (ACACB), FBP1, and TIGAR
were compared using adjusted p-value (Benjamini–Hochberg). For an unsupervised hierarchical
cluster analysis, Ward linkage method was used together with the Pearson distance for both sample
and gene clustering. Among 1093 BRCA patient samples with subtype information, mutational
status of BRCA1/2, PIK3CA, and p53 were available in 973 samples for hierarchical cluster analysis.
The statistical significance of PFKP, ACC2, FBP1, and TIGAR according to the breast cancer subtypes
was determined by Tukey’s HSD (honestly significant difference) test.
3. Glycolysis and Gluconeogenesis
Biosynthesis and related anabolic pathways have been investigated in cancer primarily in the
context of targeting and controlling the vast growth potential of the tumor. Glucose serves as a
primary energy source for proliferation in both normal and cancer cells in ideal glucose-rich conditions.
It is not surprising that aerobic glycolysis is evident in proliferating cancer cells, as described early
by Warburg [19]. However, the glycolytic pathway is highly inefficient in terms of ATP generation
compared to oxidative phosphorylation, so that normal proliferative mammal cells channel their final
glycolytic metabolites into the mitochondria to meet their bioenergy demand [20]. Under constant
glucose supply, proliferating cancer cells have been proposed to depend on aerobic glycolysis in
order to provide glycolytic intermediates for excessive macromolecular biosynthesis and to rapidly
produce ATP [21,22]. It should be noted that glucose level in human cancer tissue is much less than its
physiologic concentration [19,23].
The following metabolic pathways are illustrated in Figure 1. There are three critical and
irreversible catalytic steps in aerobic glycolysis [24,25]. The hexokinase (HK), the first rate-limiting
step in glycolysis, regulates the intracellular glucose transport through glucose phosphorylation. HK
converts glucose into glucose-6-phosphate (G6P), which proceeds along the glycolytic pathway or flux
into the PPP depending on the cells metabolic demand. In the glycolytic stream, G6P is converted to
fructose-6-phosphate (F6P), which is then catalyzed by the key rate-liming step phosphofructokinase-1
(PFK-1) into fructose-1,6-bisphosphate (F1,6BP). PFK-1, a gatekeeper of glycolysis, has three isoforms:
PFKL (liver), PFKM (muscle), and PFKP (platelet) [26]. Cancer cells mainly utilize the PFKP for
glycolysis and Snail suppresses PKFP to redirect glucose flux into PPP, resulting in NADPH production
via oxidative branch [16]. While knockdown of Snail increases amino acid synthesis and lactate
production, Snail-loss cancer cells are susceptible to cell death by oxidative stress or glucose starvation
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due to decreased NADPH level [16]. An additional critical enzyme activated in late glycolysis is
pyruvate kinase M2, an isoform of pyruvate kinase that shifts the glucose flux to lactate formation in
cancer cells contrary to physiologic aerobic mitochondrial respiration [27].
Gluconeogenesis shares reversible enzymes with glycolysis with two exemptions. FBP1 and
glucose-6-phosphatase in gluconeogenesis are inverse reaction steps of PFK-1 and HK in glycolysis,
respectively. FBP1 is the rate-limiting step in gluconeogenesis that either releases glucose into the
blood stream or shifts the metabolites into the PPP [28,29]. In a physiologic condition, gluconeogenesis
mainly occurs in liver and kidney under hypoglycemic condition, while FBP-1 is downregulated in
specific types of human cancer [30,31]. Although FBP-1 is a Snail target gene, metabolic outcomes by
loss of FBP1 in human cancer, whether increased mitochondrial flux or lactate production, are not yet
well-understood, particularly under starved environment.
In general, counter-opposing PFK-1 and FBP1 are allosterically regulated by metabolite fructose
2,6-bisphosphate (F2,6BP), which is catalyzed by bifunctional PFK-2/FBP2 through glucose-associated
hormones such as insulin, epinephrine, and glucagon. This indicates that F2,6BP contributes to
glucose flux regulation [32,33]. F2,6BP increases the affinity of PFK-1 for F6P, enhancing glycolysis
and inhibiting gluconeogenesis [34]. p53 downstream gene TP53-induced glycolysis and apoptosis
regulator (TIGAR) has features similar to those of the bisphosphatase domain in FBP2 and degrades
F2,6BP [35,36]. During cellular stress and early tumor suppressor gene p53 activation, TIGAR inhibits
glycolysis, turning the carbon flux toward the PPP [35]. Therefore, activation of TIGAR and loss of
PFK-1 play similar roles in terms of PPP flux.
4. Pentose Phosphate Pathway and NADPH Generation
The PPP is a main source for NADPH, which provides the major reducing equivalents for FAS and
oxidative stress. Alternative NADPH, especially in glucose-deprived situations, is produced by FAO in
the mitochondria [37]. PPP activation is essential in both the anabolic and catabolic pathways of cancer.
It provides phosphopentoses and ribonucleotides for biosynthesis, as well as supporting FAS [38].
Oxidative phosphorylation highly relies on redox homeostasis as reactive oxygen species (ROS) are
chiefly produced during mitochondrial activity [39,40]. The PPP is composed of two continuous
branches, the oxidative branch, responsible for NADPH generation, and the non-oxidative branch,
which provides reversible flows of glycolytic intermediates [5]. NADPH produced by oxidative PPP
is also required for one-carbon folate metabolism [41]. The PPP is tightly regulated along with the
glycolytic pathway and the carbon flux can either flow into the mitochondria or into gluconeogenesis
and back to the PPP. This allosteric regulation gives flexibility to cancer cells in meeting the demands
of metabolic reprogramming. Being a gatekeeper of glycolysis, PFPK plays a key role in regulating
flux control between glycolysis and PPP. Interestingly, knockdown of PFKP in breast cancer cells
induced dormancy-like cell cycle arrest with gain of resistance against oxidative stress, such as
glucose starvation or paclitaxel treatment [16], indicating the importance of flux control between
glycolysis and PPP. The glucose transport is shifted into the oxidative branch of PPP through G6P
based on levels of ribulose-5-phosphate (Ribu5P), NADPH, and ATP as determined by metabolic
demand [5,16,42]. The first product of the oxidative branch is Ribu5P, which can be isomerized
and used as a nucleotide precursor or passed on to the non-oxidative branch. The non-oxidative
branch of PPP is tightly interconnected with glycolysis and shares intermediate metabolites F6P and
glyceraldehyde-3-phosphate (G3P or GADP). This reversible allosteric link is catalyzed by transketolase
and transaldolase [43]. This flux can be recycled into the PPP though gluconeogenesis controlled by
FBP1 to maintain the high NADPH levels required in physiologic tissue, such as liver, fat, and neural
tissue [44]. Although the regulation of recycled flux in cancer is not understood in detail, metabolites
may proceed into either upstream gluconeogenesis or the downstream TCA cycle based on oncogenic
regulation of metabolic demand by bi-directional enzymes, such as aldolase and G3P dehydrogenase.
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5. Fatty Acid Oxidation and ATP Formation
As glucose-deficient conditions impair the glycolytic pathway, cancer cells have to reduce their
proliferation rate while increasing ATP and NADPH generation to promote survival. Due to lack of
glucose intake, cancer cells acquire metabolites for oxidation from fatty acids, which are consumed in the
citric acid cycle and oxidative phosphorylation to produce ATP. FAO, also known as beta-oxidation, is a
catabolic countenance of the fatty acid metabolism and is linked with FAS in an exclusive manner [45].
FAS intermediate malonyl-CoA inhibits the main transport system, carnitine palmitoyltransferase 1
(CPT1), which transports exogenous or glucose-derived fatty acetyl-CoA into the mitochondria for
beta-oxidation and later into oxidative phosphorylation [46]. Malonyl-CoA is produced via ACC,
a gatekeeper for the reciprocal regulation between mutually exclusive FAO and FAS [47,48]. FAS
requires substantial NADPH consumption for anabolic construction, while FAO principally produces
ATP and NADPH. Therefore, in a glucose-starved condition, malonyl-CoA is a critical determinant of
mitochondrial catabolic metabolism. During FAO, malonyl-CoA is controlled by ACC2 at the outer
mitochondrial membrane, while ACC1 is located in the cytoplasm and mediates FAS [49]. In clinical
samples, ACC2 was suppressed in various cancers, while ACC1 level was similar in neoplastic and
normal tissue, indicating ACC2 activity and abundance comprise a core mitochondrial regulator in
cancer [18]. Snail increased mitochondrial FAO and suppressed FAS by suppression of ACC2, reduced
malonyl-CoA production, and subsequent increased CPT1 activity and TCA metabolites [18].
There has been growing evidence of the role of FAO during metastasis. FAO-associated genes are
upregulated, inducing a metabolic shift during lymphatic metastasis [50]. Reduced intracellular ATP
stimulates the liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK) pathway, which in turn
inhibits ACC2. In addition, AMPK induces alternative NADPH for redox homeostasis in advanced
glucose deficiency, wherein the PPP may be impaired [37]. In addition to glucose-depleted conditions,
metastatic cells frequently encounter acidosis, which metabolically reprograms them toward FAO
for adoption by mitochondrial hyperacetylation and ACC2 suppression [19,51,52]. These findings
reinforce the significance of catabolic metabolism for tumor survival in stressful environments.
6. Paradox of Snail-Mediated Catabolic Metabolism
Snail is a main transcription factor of EMT, directly repressing E-cadherin transcription [7].
Snail transcript and protein abundance are regulated by oncogenic pathways such as Wnt, p53,
transforming growth factor-β (TGF-β) superfamily, and receptor tyrosine kinase signaling [53–58].
In glucose-deficient conditions, which represent the metabolic status of the metastatic procedure,
Snail specifically activates catabolic reprogramming. We have reported that Snail directly suppresses
PFKP and ACC2 transcription, thereby switching the glycolytic flux into the PPP to enhance NADPH
generation and stimulate oxidative phosphorylation via FAO, respectively [16,18]. ACC2 levels varied
among breast cancer molecular subtypes in clinical samples, in an inverse relation to Snail with a
reliance on p53 status. This implies that different clinical prognoses in molecular subtypes can be
explained by Snail activity and p53 status, which we further investigated as described later in this
article. In addition, other studies have shown that Snail inhibits FBP1 by DNA promoter methylation, a
rate limiting enzyme of gluconeogenesis which has been proposed to enhance glycolysis [17,42,59,60].
As the gluconeogenesis by FBP1 is highly endergonic, the metabolic advantage by loss of FBP1 in
cancer cells is quite clear. However, Snail paradoxically suppresses the rate limiting steps in glycolysis
and gluconeogenesis via suppression of PFKP and FBP-1, respectively [16,42].
7. Breast Cancer Subtypes Use Different Metabolic Circuit to Gain Catabolic Advantages
Breast cancer is a heterogeneous spectrum of mammary gland-derived malignant tumors that can
be subtyped by molecular profile in terms of standard-estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (HER2). Combinations of the three molecular
profiles yield subtypes with clinically divergent implications: luminal A (ER+, PR+/−, HER2−, low
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Ki-67), luminal B (ER+, PR+/−, HER2+/−, high Ki-67), HER2 overexpression (ER−, PR−, HER2+),
and basal-like (ER-, PR-, HER2-) [61,62]. The basal-like subtype constitutes the majority of the triple
negative cases and generally has a worse prognosis than the luminal A or B subtype [61,63–65].
The basal-like subtype shows a higher p53-loss rate along with increased Snail abundance than do
the luminal subtypes (mainly p53 wild type) [18,61,66]. As the triple negative breast cancers (TNBC)
have an aggressive clinical course and lack treatment options, there have been various attempts to
unravel their pathogenesis. EMT markers, including Snail, are highly evident in TNBC [18,67–71]. It
should not be assumed that differentiated luminal subtypes lack EMT gene expression, but rather the
EMT markers are selectively expressed and dedifferentiated [72]. The luminal B subtype has a high
proliferative profile that typically opposes EMT activity [73]. Nevertheless, luminal subtypes have to
enhance EMT transcription factors to overcome environmental stress and promote metastasis just as
does TNBC.
The paradoxical suppression of PFKP and FBP1 by Snail suggested molecular subsets of different
catabolic metabolism in breast cancer, leading us to further investigate metabolic-dependency based on
breast cancer subtypes. We analyzed data from clinical samples from TCGA (The Cancer Genome Atlas)
to determine transcript abundance of PFKP and FBP1 in breast cancer (BRCA) according to intrinsic
subtype and mutational status of BRCA1/2, PIK3CA, and p53. Interestingly, clustering analysis with
PFKP and FBP1 revealed distinct breast cancer subtypes, and transcript abundance of the two genes
were inversely correlated (Figure 2A). The PFKP is mainly suppressed in luminal types having PIK3CA
mutation while the FBP1 is suppressed in most basal-like types of breast cancer having p53 mutation,
indicating a different catabolic circuit according to subtype and mutational status of PIK3CA and
p53. While breast cancers having the BRCA mutation tend to favor the glycolytic pathway, the trend
is not conclusive due to the limited number of BRCA mutation samples (Figure 2B,C). However,
PIK3CA mutation in breast cancer was accompanied by lowered PFKP and higher FBP1, while p53
mutation revealed higher PFKP and lowed FBP1 (Figure 2D,E). These suggest that luminal types of
p53 wt and PIK3CA mut breast cancer actively utilize PPP via suppression of PFKP and activation of
FBP1 (Figure 2F). It should be noted that activation of gluconeogenesis may efficiently increase PPP
flux [74]. In contrast, TNBC having p53 mutation and low frequency of PIK3CA mutation may have
high glycolytic activity. These results indicate that EMT-mediated catabolic metabolism depends on
breast cancer subtypes and oncogenic mutational status.
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Figure 2. Mutual exclusive and differential expression of PFKP and FBP1 according to the breast cancer
subtypes. (A) Unsupervised hierarchical cluster analysis of breast cancer patient samples in The Cancer
Genome Atlas (TCGA) using PFKP and FBP1 to discriminate metabolic subsets with mutational status
of BRCA1/2, PIK3CA, and p53 (left panel). Luminal subtypes show PFKP suppression with PIK3CA
mutation (PPP dependent subset), while basal-like subtype shows FBP1 suppression (glycolytic subset)
having p53 mutation. Pearson distance analysis with a negative distance correlation of PFKP and
FBP1 with divergent clusters of breast cancer subtypes (right panel, coefficient = −0.501, p < 0.001).
(B–F) Comparison of PFKP or FBP1 transcript abundances according to mutational status of BRCA1
(wt, n = 956; mut, n = 17) (B), BRCA2 (wt, n = 956; mut, n = 17) (C), PIK3CA (wt, n = 657; mut, n =
316) (D), and p53 (n = 675; mut, n = 298) (E) and breast cancer subtypes (F). Statistical significance was
determined by Tukey’s HSD (honestly significant difference) test.
As the ACC2 comprises a Snail target resulting in increased FAO [18], we speculated that an
FBP1-loss subtype, such as TNBC, is accompanied by suppression of ACC2 in breast cancer to support
efficient mitochondrial catabolic metabolism. Interestingly, FBP1 and ACC2 transcript abundance
were correlated, and ACC2 is suppressed in FBP1-loss basal-like subtype of breast cancer having
p53 mutation (Figure 3A). Previously, we reported that ACC2 abundance is inversely correlated in
higher Snail expression breast cancer samples having p53 mutation [18]. However, ACC2 abundance
was correlated to neither PIK3CA nor BRCA mutation (Figure 3B). These results suggest that TNBC
showing high glycolytic activity actively utilizes mitochondrial FAO. As noted, increased expression of
TIGAR activates PPP flux. Analyzing TIGAR expression according to breast cancer subtypes, we found
that TIGAR is increased in the FBP1-loss basal-like subtype of breast cancer (Figure 4). These results
Cells 2020, 9, 2064 8 of 13
suggest that PPP is still important in TNBC regardless of glycolysis and mitochondrial-dependent
catabolic metabolism [74].
Figure 3. FBP-loss accompanies activation of FAO by down-regulation of ACC2 in basal-like subtype.
(A) Unsupervised hierarchical cluster analysis of breast cancer patient samples in The Cancer Genome
Atlas (TCGA) using FBP1 and ACC2 (ACACB) to discriminate between metabolic subsets of tumors
with breast cancer subtypes (left panel). FBP1 and ACC2 were simultaneously suppressed in basal-like
subtype having p53 mutation (dot lined box). Pearson distance analysis with a positive distance
correlation of FBP1 and ACC2 (right panel, coefficient = −0.327, p < 0.001). (B) ACC2 transcript
abundance according to the BRCA1/2 or PIK3CA mutation in breast cancer samples.
Figure 4. TIGAR is increased in FBP1-loss basal-like subtype of breast cancer. Comparison of TIGAR
transcript levels according to PFKP (left panel), FBP1 (middle panel), and breast cancer subtypes (right
panels). TIGAR expression was significantly higher in PFKP high, FBP1 low subsets, and basal-like
subtype. Statistical significance was determined by Tukey’s HSD (honestly significant difference) test.
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8. Conclusions
In conclusion, metabolic reprogramming toward catabolism is essential for cancer cell survival
and can be separately achieved in respective intrinsic subtypes of breast cancer via different opposing
oncogenic regulations of Snail (Figure 5). The catabolic metabolism of luminal types of breast cancer
largely depends on resulting PPP flux, while the basal-like subtypes actively utilize mitochondrial FAO.
Our results provide diverse circuits of catabolic metabolism in human cancer and a novel therapeutic
approach involving metabolic targeting according to cancer subtype.
Figure 5. Proposed model of EMT-mediated catabolic metabolism in breast cancer subtypes. Proposed
divergent metabolic models of PPP-dependent luminal subtype (left) and a FAO-dependent basal-like
subtype (right) of breast cancer indicate Snail involvement in catabolic metabolism and cancer
cell survival. Abbreviations: PPP, pentose phosphate pathway; FAO, fatty acid oxidation; ACC2,
acetyl-CoA carboxylase 2; CPT1, carnitine palmitoyltransferase I; G6P, glucose 6-phosphate; R5P,
ribose-5-phosphate; F6P, fructose 6-phosphate; TIGAR, TP53-induced glycolysis and apoptosis regulator;
PFK-1 phosphofructokinase-1; FBP1, fructose 1,6-bisphosphatase 1; F1,6BP, fructose 1,6-bisphosphate;
DHAP, dihydroxyacetone phosphate.
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